Eisai reports positive data from long-term Fycompa study

Eisai has announced results from a new clinical study showing the long-term safety and efficacy of Fycompa, its approved treatment for epilepsy.

Data from the 307 study, a three-year trial, showed the first-in-class epilepsy treatment is able to control and reduce seizures over sustained periods of time, as well as being well-tolerated over the entire duration of the study.

Of the 1,216 adolescents and adults involved in the trial, up to 90 percent achieved a reduction in secondarily generalised seizures and five percent achieved seizure freedom lasting at least one year.

Fycompa is manufactured by Eisai in the UK and has been approved in Europe since July 2012.

Professor Bernhard Steinhoff of Germany's Epilepsiezentrum Kork said: "The 307 study data provides evidence of the sustained seizure control and freedom that long-term perampanel use can provide people with epilepsy, regardless of where they live in the world."

This comes after the firm shared trial data last month showing the long-term benefits its drug Zonegran can deliver to children with partial epilepsy.